| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.32 | 1e-19 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.31 | 2e-18 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-15 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.22 | 4e-10 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.32 | 6e-10 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.33 | 1e-09 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-09 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-08 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.21 | 1e-07 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-07 |